Dynamic aspects of macrophage polarization during atherosclerosis progression and regression

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Peled, Michael ^a   Fisher, Edward A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cholesterol; Macrophages; Polarization; Regression

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CD36 ANTIGEN; CHOLESTEROL; CRYOPYRIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; OXIDIZED LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; DISEASE COURSE; HUMAN; HYPOXIA; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PHENOTYPE; REMISSION; REVIEW; T LYMPHOCYTE;

EID: 84919394753     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00579     Document Type: Review

References (91)

1. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol (1995) 15(5):551-61. doi: 10.1161/01.ATV.15.5.551
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med (1999) 340(2):115-26. doi:10.1056/NEJM199901143400207
3. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 17(11):1410-22. doi:10.1038/nm.2538
4. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol (2011) 12(3):204-12. doi:10.1038/ni.2001
5. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med (2008) 5(2):91-102. doi:10.1038/ncpcardio1086
6. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity (2014) 41(1):21-35. doi:10.1016/j.immuni.2014.06.013
7. Distel E, Barrett TJ, Chung K, Girgis NM, Parathath S, Essau CC, et al. miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. Circ Res (2014) 115(9):759-69. doi:10.1161/CIRCRESAHA.115.304164
8. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 164(12):6166-73. doi:10.4049/jimmunol.164.12.6166
9. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity (2010) 32(5):593-604. doi:10.1016/j.immuni.2010.05.007
10. Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Herrley E, et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res (2012) 110(3):416-27. doi:10.1161/CIRCRESAHA.111.253377
11. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. Circulation (1996) 94(8):2013-20. doi:10.1161/01.CIR.94.8.2013
12. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American heart association. Arterioscler Thromb Vasc Biol (1995) 15(9):1512-31. doi:10.1161/01.ATV.15.9.1512
13. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2000) 20(5):1262-75. doi:10.1161/01.ATV.20.5.1262
14. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol (2000) 157(4):1259-68. doi:10.1016/S0002-9440(10)64641-X
15. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A (2007) 104(49):19446-51. doi:10.1073/pnas.0706832104
16. Feig JE, Parathath S, Rong JX, Mick SL, Vengrenyuk Y, Grauer L, et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation (2011) 123(9):989-98. doi:10.1161/CIRCULATIONAHA.110.984146
17. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A (2011) 108(17):7166-71. doi:10.1073/pnas.1016086108
18. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res (2010) 107(6):737-46. doi:10.1161/CIRCRESAHA.109.215715
19. Stöger JL, Gijbels MJ, van der Velden S, Manca M, der Loos CM, Biessen EA, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis (2012) 225(2):461-8. doi:10.1016/j.atherosclerosis.2012.09.013
20. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine (2008) 42(2):145-51. doi:10.1016/j.cyto.2008.01.006
21. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 56(7):1761-72. doi:10.2337/db06-1491
22. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr (2008) 87(5):1219-23.
23. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes (2008) 57(6):1470-81. doi:10.2337/db07-1403
24. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet (2000) 25(2):187-91. doi:10.1038/76048
25. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 347(3):185-92. doi:10.1056/NEJMoa012673
26. Kiechl S, Wiedermann CJ, Willeit J. Toll-like receptor 4 and atherogenesis. Ann Med (2003) 35(3):164-71. doi:10.1080/07853890310008215
27. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol (2003) 23(12):e61-4. doi:10.1161/01.ATV.0000101191.92392.1D
28. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A (2004) 101(29):10679-84. doi:10.1073/pnas.0403249101
29. Stepankova R, Tonar Z, Bartova J, Nedorost L, Rossman P, Poledne R, et al. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb (2010) 17(8):796-804. doi:10.5551/jat.3285
30. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008) 105(43):16731-6. doi:10.1073/pnas.0804812105
31. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 464(7293):1357-61. doi:10.1038/nature08938
32. Lim RS, Suhalim JL, Miyazaki-Anzai S, Miyazaki M, Levi M, Potma EO, et al. Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging. J Lipid Res (2011) 52(12):2177-86. doi:10.1194/jlr.M018077
33. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol (2013) 14(8):812-20. doi:10.1038/ni.2639
34. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (2003) 23(4):656-60. doi:10.1161/01.ATV.0000064374.15232.C3
35. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 108(2):235-48. doi:10.1161/CIRCRESAHA.110.223875
36. Kim TW, Febbraio M, Robinet P, Dugar B, Greene D, Cerny A, et al. The critical role of IL-1 receptor-associated kinase 4-mediated NF-kappaB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis. J Immunol (2011) 186(5):2871-80. doi:10.4049/jimmunol.1002242
37. Rekhter M, Staschke K, Estridge T, Rutherford P, Jackson N, Gifford-Moore D, et al. Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation. Biochem Biophys Res Commun (2008) 367(3):642-8. doi:10.1016/j.bbrc.2007.12.186
38. Björkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med (2004) 10(4):416-21. doi:10.1038/nm1008
39. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by toll-like receptor 2. J Clin Invest (2005) 115(11):3149-56. doi:10.1172/JCI25482
40. Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation (2008) 118(18):1837-47. doi:10.1161/CIRCULATIONAHA.108.793869
41. Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A, et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem (2008) 283(34):22930-41. doi:10.1074/jbc.M801408200
42. Chawla A. Control of macrophage activation and function by PPARs. Circ Res (2010) 106(10):1559-69. doi:10.1161/CIRCRESAHA.110.216523
43. Spann NJ, Garmire LX, McDonald JG, Myers DS, Milne SB, Shibata N, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell (2012) 151(1):138-52. doi:10.1016/j.cell.2012.06.054
44. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med (2006) 203(5):1273-82. doi:10.1084/jem.20052205
45. Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, Scott SR, et al. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest (2012) 122(9):3114-26. doi:10.1172/JCI61758
46. Molnár E, Swamy M, Holzer M, Beck-García K, Worch R, Thiele C, et al. Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering. J Biol Chem (2012) 287(51):42664-74. doi:10.1074/jbc.M112.386045
47. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol (1996) 149(2):675-85.
48. Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A (1997) 94(9):4642-6. doi:10.1073/pnas.94.9.4642
49. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol (2011) 6:275-97. doi:10.1146/annurev-pathol-011110-130138
50. Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol (2009) 86(5):1089-95. doi:10.1189/jlb.0209115
51. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A (2003) 100(8):4736-41. doi:10.1073/pnas.0730843100
52. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ Res (2011) 108(8):985-95. doi:10.1161/CIRCRESAHA.110.233775
53. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One (2010) 5(1):e8852. doi:10.1371/journal.pone.0008852
54. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol (2013) 14(10):986-95. doi:10.1038/ni.2705
55. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 19(9):1166-72. doi:10.1038/nm.3258
56. Maitra U, Parks JS, Li L. An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol Cell Biol (2009) 29(22):5989-97. doi:10.1128/MCB.00541-09
57. Devaraj S, Jialal I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol (2011) 31(6):1397-402. doi:10.1161/ATVBAHA.111.225508
58. Iwasaki M, Mukai T, Gao P, Park WR, Nakajima C, Tomura M, et al. A critical role for IL-12 in CCR5 induction on T cell receptor-triggered mouse CD4(+) and CD8(+) T cells. Eur J Immunol (2001) 31(8):2411-20. doi:10.1002/1521-4141(200108)31:8<2411::AID-IMMU2411>3.0.CO;2-Y
59. Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC. Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-kappaB. PLoS One (2012) 7(8):e42507. doi:10.1371/journal.pone.0042507
60. Holman RL, McGILL HC Jr, STRONG JP, GEER JC. The natural history of atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the 20th century. Am J Pathol (1958) 34(2):209-35.
61. McMahan CA, Gidding SS, McGill HC Jr. Coronary heart disease risk factors and atherosclerosis in young people. J Clin Lipidol (2008) 2(3):118-26. doi:10.1016/j.jacl.2008.02.006
62. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 103(10):3781-6. doi:10.1073/pnas.0511043103
63. Chereshnev I, Trogan E, Omerhodzic S, Itskovich V, Aguinaldo JG, Fayad ZA, et al. Mouse model of heterotopic aortic arch transplantation. J Surg Res (2003) 111(2):171-6. doi:10.1016/S0022-4804(03)00039-8
64. Lieu HD, Withycombe SK, Walker Q, Rong JX, Walzem RL, Wong JS, et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation (2003) 107(9):1315-21. doi:10.1161/01.CIR.0000054781.50889.0C
65. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest (2011) 121(5):2025-36. doi:10.1172/JCI43802
66. Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, De Geest B. Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med (Berl) (2011) 89(6):555-67. doi:10.1007/s00109-011-0722-x
67. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol (2005) 25(2):436-41. doi:10.1161/01.ATV.0000152613.83243.12
68. Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis (2013) 227(1):125-9. doi:10.1016/j.atherosclerosis.2012.12.026
69. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Puré E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation (1999) 100(17):1816-22. doi:10.1161/01.CIR.100.17.1816
70. Reis ED, Li J, Fayad ZA, Rong JX, Hansoty D, Aguinaldo JG, et al. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. J Vasc Surg (2001) 34(3):541-7. doi:10.1067/mva.2001.115963
71. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation (2001) 104(20):2447-52. doi:10.1161/hc4501.098952
72. Zhao Y, Black AS, Bonnet DJ, Maryanoff BE, Curtiss LK, Leman LJ, et al. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J Lipid Res (2014) 55(10):2053-63. doi:10.1194/jlr.M049262
73. Hewing B, Parathath S, Barrett T, Chung WK, Astudillo YM, Hamada T, et al. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2014) 34(4):779-89. doi:10.1161/ATVBAHA.113.303044
74. Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science (2010) 328(5985):1570-3. doi:10.1126/science.1189862
75. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest (2011) 121(7):2921-31. doi:10.1172/JCI57275
76. Olofsson SO, Asp L, Boren J. The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol (1999) 10(4):341-6. doi:10.1097/00041433-199908000-00008
77. Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs (2002) 16(1):3-10. doi:10.2165/00063030-200216010-00001
78. Nagareddy PR, Murphy AJ, Stirzaker RA, Hu Y, Yu S, Miller RG, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 17(5):695-708. doi:10.1016/j.cmet.2013.04.001
79. Parathath S, Grauer L, Huang LS, Sanson M, Distel E, Goldberg IJ, et al. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes (2011) 60(6):1759-69. doi:10.2337/db10-0778
80. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A (2004) 101(32):11779-84. doi:10.1073/pnas.0403259101
81. Sanson M, Distel E, Fisher EA. HDL induces the expression of the M2 macrophage markers arginase 1 and Fizz-1 in a STAT6-dependent process. PLoS One (2013) 8(8):e74676. doi:10.1371/journal.pone.0074676
82. Colin S, Fanchon M, Belloy L, Bochem AE, Copin C, Derudas B, et al. HDL does not influence the polarization of human monocytes toward an alternative phenotype. Int J Cardiol (2014) 172(1):179-84. doi:10.1016/j.ijcard.2013.12.168
83. De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol (2014) 15(2):152-60. doi:10.1038/ni.2784
84. Wilhelm AJ, Zabalawi M, Owen JS, Shah D, Grayson JM, Major AS, et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem (2010) 285(46):36158-69. doi:10.1074/jbc.M110.134130
85. Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR. Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta (2012) 1821(3):513-21. doi:10.1016/j.bbalip.2011.08.003
86. Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med (2012) 4(10):1072-86. doi:10.1002/emmm.201201374
87. Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, et al. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol (2008) 180(8):5707-19. doi:10.4049/jimmunol.180.8.5707
88. Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol (2012) 189(7):3508-20. doi:10.4049/jimmunol.1200662
89. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol (2003) 5(9):781-92. doi:10.1038/ncb1035
90. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 8(12):958-69. doi:10.1038/nri2448
91. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest (2005) 115(9):2434-43. doi:10.1172/JCI24819